Dr Simon Calaminus

Matrix Metalloproteinase Activated Multimodal 'Theranostic' Drug Delivery Imaging Agents For Thrombosis Mar 1, 2020 - Aug 31, 2024

Effect of hypoxia on prostacyclin-mediated inhibition of platelet function Jan 1, 2023 - Dec 31, 2025
Tissue hypoxia occurs in multiple cardiovascular and pulmonary conditions that have platelet activation or hyperreactivity, including myocardial infarction, stroke, chronic obstructive pulmonary disease (COPD) and sleep apnoea. However, knowledge on... Read More about Effect of hypoxia on prostacyclin-mediated inhibition of platelet function.

Microplastics as an emerging and iatrogenic threat in the healthcare setting Apr 1, 2024 - Mar 31, 2025
Microplastics as an emerging pollutant in healthcare settings, focussing on the operating room.

Wolfson Equipment bid 2023 - Confocal Imaging ZEISS Elyra 7 with Lattice SIM² Oct 1, 2024 - Sep 30, 2029

TARGETING THE MYOSIN LIGHT CHAIN PHOSPHATASE WITH PEPTIDE DISRUPTORS: A NOVEL ANTIPLATELET THERAPEUTIC APPROACH Jul 3, 2023 - Jul 2, 2026
Platelet activation and thrombus formation play key roles in the pathogenesis of ischaemic cardiovascular diseases, one of the major causes of death in the UK. Many antiplatelet agents have been developed to manage these conditions; however, they are... Read More about TARGETING THE MYOSIN LIGHT CHAIN PHOSPHATASE WITH PEPTIDE DISRUPTORS: A NOVEL ANTIPLATELET THERAPEUTIC APPROACH.

RISE: Establishing super-Resolution Imaging in Hull for impactful multimorbidity ReSEarch MRC Equipment bid 2024 - Confocal Imaging ZEISS Elyra 7 with Lattice SIM² Oct 1, 2024 - Sep 30, 2029

Is zinc a critical modulator of cyclic nucleotide signalling? Oct 1, 2019 - Dec 31, 2022
inc (Zn2+) deficiency is present in multiple conditions from obesity to cancer. However importantly Zn2+ deficiency can lead to a bleeding phenotype.In this proposal we investigate how Zn2+ is important for the control of platelet cyclic nucleotide... Read More about Is zinc a critical modulator of cyclic nucleotide signalling?.

Platelet cAMP signalling controls thrombosis through enhanced embolisation Oct 1, 2015 - Sep 30, 2018
The activation of protein kinase A (PKA) by prostacyclin inhibits platelet activation and therefore modulates arterial thrombosis. However, the role of PKA in controlling the stability of pre-existing thrombi is unclear. The stability of thrombi is r... Read More about Platelet cAMP signalling controls thrombosis through enhanced embolisation.

ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging Feb 1, 2017 - Jan 31, 2020
Cardiovascular diseases (CVD) including heart attacks and strokes constitute the leading cause of mortality in the UK. The pathology underlying CVD is called atherothrombosis and is a complex, multi-cellular-inflammatory disorder. Central to this is... Read More about ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging.

Dr Simon Calaminus' Projects (9)